Health and Child Rights Overshadowed by Regulatory Lapses

The discussion follows repeated incidents of contaminated and substandard medicines, particularly paediatric syrups, which have led to child fatalities both in India and abroad. These tragedies have exposed gaps in drug testing, export oversight, and accountability, highlighting how regulatory lapses are undermining children’s right to health and life.

Background

• India is often called the “Pharmacy of the World”, being one of the largest producers and exporters of generic medicines.
• However, over the past few years, WHO and foreign regulators have flagged several Indian-manufactured cough syrups for containing toxic contaminants such as ethylene glycol (EG) and diethylene glycol (DEG) — industrial solvents harmful to humans.
• Notable cases include:
  • The Gambia (2022): At least 70 child deaths linked to Indian-made syrups.
  • Uzbekistan (2022–23): Similar incidents of child deaths traced to contaminated drugs.
  • Recent Domestic Cases: Sporadic reports of substandard formulations in paediatric use within India.

The Core Issue

The tragedy lies not just in the contamination itself but in the failure of the regulatory ecosystem to prevent, detect, and penalize such violations.

1. Fragmented Oversight:
   • India’s Central Drugs Standard Control Organisation (CDSCO) coexists with State Drug Controllers, leading to overlap and coordination gaps.
   • Many small and medium drug manufacturers escape rigorous inspection due to capacity shortages.
2. Inadequate Testing Infrastructure:
   • Limited and unevenly distributed drug testing laboratories across states.
   • Many lack accreditation or advanced testing equipment for contaminants like EG/DEG.
3. Weak Enforcement & Accountability:
   • Penalties for non-compliance remain light, rarely leading to prosecution.
   • The absence of mandatory recall mechanisms delays corrective action.
4. Export Oversight Gap:
   • Drugs for export often bypass domestic scrutiny under the assumption of compliance with importing country regulations.

Impact on Child Rights

• Right to Life (Article 21): The Constitution implicitly guarantees health as part of the right to life; contaminated medicines directly violate this right.
• UN Convention on the Rights of the Child (CRC): India, as a signatory, must ensure the “highest attainable standard of health” for all children.
• Public Trust Erosion: Families’ trust in public healthcare and India’s pharmaceutical reputation is severely affected.

Government and Institutional Response

• The Union Ministry of Health has initiated stricter protocols for testing and mandated risk-based inspections.
• The Central Drugs Standard Control Organisation (CDSCO) has ordered random sampling and joint audits with state agencies.
• The Drugs, Medical Devices, and Cosmetics Bill, 2023 (yet to be enacted) proposes:
  • Stronger penalties for manufacturing substandard drugs.
  • Better regulation of exports.
  • Digital tracking of manufacturing and distribution.

However, experts argue that systemic reform, not isolated crackdowns, is needed.